The Colon Vitamin contains micronutrients and antioxidants that have been shown in scientific studies to promote colon health. Ideal for people with a history of colon cancer, a history of colon polyps, or anyone concerned with promoting their colon health.

1. The Science Behind The Colon Vitamin
October 2014 1

2. The Colon Vitamin contains
natural micronutrients and antioxidants
that have been shown in scientific studies to
promote colon health.*
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
October 2014 2

3. Natural Micronutrients & Antioxidants
Ingredients Role Impact shown in studies
Micronutrients
Vitamin B2 An important factor in folate metabolism Protects against polyp formation
Vitamin B6 Prevents abnormalities in DNA synthesis, repair, and
methylation
Reduced colorectal cancer risk
Folate Increases DNA methylation in colon cells which is
important in DNA synthesis & gene stability
Reduced risk of recurrent polyps
Calcium Appears to reduce the risk of colorectal cancer by
binding bile & fatty acids and by inhibiting
pathological crypt activity
Reduced risk of polyp formation
Antioxidants
Beta Carotene An antioxidant with antineoplastic activity Reduced risk of recurrent polyps
Vitamin D Normal & cancerous cells express Vitamin D
receptors which induce anti-cancer reactions
Reduced colorectal cancer risk
Selenium Protects colon cells against a wide range of external
and internal stressors, including inhibiting malignant
colon cell proliferation
Reduced risk of polyp formation and
colorectal cancer risk
Curcumin An antioxidant with antineoplastic activity that
potentiates the effect of chemotherapy in colon and
other cancers
Phase 3 studies underway in patients
with colon cancer
October 2014 3

4. Beta Carotene: non-smokers & non-alcohol drinkers saw a decrease in the risk of
one or more recurrent adenomatous polyps.
Methods: We studied the effect of β-carotene supplementation on colorectal
adenoma recurrence among subjects in a multicenter double-blind, placebo-controlled
clinical trial of antioxidants for the prevention of colorectal
adenomas. A total of 864 subjects who had had an adenoma removed and
were polyp-free were randomly assigned (in a factorial design) to receive β-
carotene (25 mg or placebo) and/or vitamins C and E in combination (1000
mg and 400 mg, respectively, or placebo), and were followed with
colonoscopy for adenoma recurrence 1 year and 4 years after the qualifying
endoscopy. A total of 707 subjects had two follow-up examinations and
provided smoking and alcohol use data. Adjusted multivariate risk ratios
(RRs) and 95% confidence intervals (CIs) were used to assess the effects of β-
carotene on adenoma recurrence.
Results: Among subjects who neither smoked cigarettes nor drank alcohol, β-
carotene was associated with a marked decrease in the risk of one or more
recurrent adenomas (RR = 0.56, 95% CI = 0.35 to 0.89), but β-carotene
supplementation conferred a modest increase in the risk of recurrence
among those who smoked (RR = 1.36, 95% CI = 0.70 to 2.62) or drank (RR =
1.13, 95% CI = 0.89 to 1.43). For participants who smoked cigarettes and also
drank more than one alcoholic drink per day, β-carotene doubled the risk of
adenoma recurrence (RR = 2.07, 95% CI = 1.39 to 3.08; P for difference from
nonsmoker/nondrinker RR < .001).
Conclusion: Alcohol intake and cigarette smoking appear to modify the effect
of β-carotene supplementation on the risk of colorectal adenoma recurrence.
Journal of the National Cancer Institute 2003; 95: 717-722
October 2014 4

5. Calcium: dietary calcium is associated with decreased incidence of colon polyps.
Epidemiology. 7(3):264-268), May 1996
October 2014 5

6. Folic Acid (Folate): supplementation is associated with reduced rate of recurrent
adenomatous polyps.
World Journal of Gastroenterology 2008; 14: 4492-4498
AIM: To determine whether folic acid supplementation will reduce the
recurrence of colorectal adenomas, the precursors of colorectal cancer, we
performed a double-blind placebo-controlled trial in patients with
adenomatous polyps.
METHODS: In the current double-blind, placebo-controlled trial at this VA
Medical Center, patients with colorectal adenomas were randomly assigned
to receive either a daily 5 mg dose of folic acid or a matched identical
placebo for 3 years. All polyps were removed at baseline colonoscopy and
each patient had a follow up colonoscopy at 3 years. The primary endpoint
was a reduction in the number of recurrent adenomas at 3 years.
RESULTS: Of 137 subjects, who were eligible after confirmation of polyp
histology and run-in period to conform compliance, 94 completed the study;
49 in folic acid group and 45 in placebo group. Recurrence of adenomas at 3-
year was compared between the two groups. The mean number of recurrent
polyps at 3-year was 0.36 (SD, 0.69) for folic acid treated patients compared
to 0.82 (SD, 1.17) for placebo treated subjects, resulting in a 3-fold increase
in polyp recurrence in the placebo group. Patients below 70 years of age and
those with left-sided colonic adenomas or advanced adenomas responded
better to folic acid supplementation.
CONCLUSION: High dose folic acid supplementation is associated with a
significant reduction in the recurrence of colonic adenomas suggesting that
folic acid may be an effective chemopreventive agent for colorectal
neoplasia.
October 2014 6

7. Selenium: supplementation may prevent the development of adenomatous polyps.
American Journal of Gastroenterology 2002; 97: 2103-2108
OBJECTIVE: Selenium is a fundamental nutrient to human health that might have
anticarcinogenic effects. Previous studies have assessed the possible relationship
of selenium status to colorectal adenomas with controversial results. We
primarily aimed to assess the relationship of serum selenium status with the
presence of large size colorectal adenomas in subjects living in a poor selenium
region. The serum selenium status in colorectal cancer was also evaluated.
METHODS: Serum selenium levels were measured in 28 patients with large size
sporadic adenomatous polyps, 24 patients with colorectal adenocarcinomas, and
35 age-matched healthy individuals. A logistic regression analysis was performed
to assess the relationship of serum selenium to colorectal adenomatous polyps
after adjusting for confounding variables (age, sex, smoking habit, and alcohol
drinking).
RESULTS: Among subjects aged 60 yr, mean serum selenium levels were
significantly lower in both patient groups (adenoma, 57.9 4.3 g/L; cancer, 43.7
6.6 g/L) than in healthy controls (88.9 8 g/L) (p = 0.0001). There were no
difference among subjects >60 yr old. A significant inverse association between
selenium status and the diagnosis of large size adenomatous polyps after
adjusting for confounding variables was found (adjusted p = 0.029). Subjects with
higher selenium status (75th percentile value of 82.11 g/L) had a lower probability
(OR = 0.17, 95% CI = 0.03–0.84) to be in the adenoma group than subjects with
lower selenium status (<82.11 g/L). This association was more marked in subjects
aged 60 yr (adjusted p value = 0.04, OR = 0.08, 95% CI = 0.007–0.91), and was not
significant in older subjects.
CONCLUSIONS: Results suggest that high selenium status may decrease the risk of
large size adenomas in a low selenium region, and that this preventive effect
seems to be exclusive to subjects 60 yr. These results will need to be confirmed in
additional epidemiological studies before recommending selenium
supplementation in patients with colon adenomas.
October 2014 7

8. Vitamin B2: high levels appear to be protective against adenomatous polyps.
Cancer Epidemiology Biomarkers and Prevention 2008; 17:
2136-2145
Background: Folate, other vitamin B cofactors, and genes involved in folate-mediated
one-carbon metabolism all may play important roles in colorectal
neoplasia. In this study, we examined the associations between dietary and
circulating plasma levels of vitamins B2, B6, and B12 and risk colorectal
adenomas.
Methods: The Aspirin/Folate Polyp Prevention Study is a randomized clinical
trial of folic acid supplementation and incidence of new colorectal adenomas
in individuals with a history of adenomas (n = 1,084). Diet and supplement
use were ascertained through a food frequency questionnaire administered at
baseline. Blood collected at baseline was used to determine plasma B-vitamin
levels. We used generalized linear regression to estimate risk ratios (RR) and
95% confidence intervals (95% CI) as measures of association.
Results: We found a borderline significant inverse association with plasma B6
[pyridoxal 5′-phosphate (PLP)] and adenoma risk (adjusted RR Q4 versus Q1,
0.78; 95% CI, 0.61-1.00; Ptrend = 0.08). This association was not modified by
folic acid supplementation or plasma folate. However, the protective
association of PLP with adenoma risk was observed only among subjects who
did not drink alcohol (Pinteraction = 0.03). Plasma B2 (riboflavin) was inversely
associated with risk of advanced lesions (adjusted RR Q4 versus Q1, 0.51;
95% CI, 0.26-0.99; Ptrend = 0.12). No significant associations were observed
between adenoma risk and plasma vitamin B12 or dietary intake of vitamin B2
and B6. When we examined specific gene-B-vitamin interactions, we observed
a possible interaction between methylenetetrahydrofolate reductase -C677T
and plasma B2 on risk of all adenomas.
Conclusion: Our results suggest that high levels of PLP and B2 may protect
against colorectal adenomas. (Cancer Epidemiol Biomarkers Prev
2008;17(8):2136–45)
October 2014 8

9. Vitamin B6: Vitamin B6 levels associated with a decreased risk of colorectal cancer.
Journal of the American Medical Association 2010;
303: 1077-1083
Context Mounting evidence indicates that vitamin B6, a coenzyme involved
in nearly 100 enzymatic reactions, may reduce the risk of colorectal cancer.
Objective To conduct a systematic review with meta-analysis of prospective
studies assessing the association of vitamin B6 intake or blood levels of
pyridoxal 5′-phosphate (PLP; the active form of vitamin B6) with risk of
colorectal cancer.
Data Sources Relevant studies were identified by a search of MEDLINE and
EMBASE databases to February 2010, with no restrictions. We also reviewed
reference lists from retrieved articles.
Study Selection We included prospective studies that reported relative risk
(RR) estimates with 95% confidence intervals (CIs) for the association
between vitamin B6 intake or blood PLP levels and the risk of colorectal,
colon, or rectal cancer.
Data Extraction Two authors independently extracted data and assessed
study quality. Study-specific RRs were pooled using a random-effects model.
Data Synthesis Nine studies on vitamin B6 intake and 4 studies on blood PLP
levels were included in the meta-analysis. The pooled RRs of colorectal
cancer for the highest vs lowest category of vitamin B6 intake and blood PLP
levels were 0.90 (95% CI, 0.75-1.07) and 0.52 (95% CI, 0.38-0.71),
respectively. There was heterogeneity among studies of vitamin B6 intake
(P = .01) but not among studies of blood PLP levels (P = .95). Omitting 1 study
that contributed substantially to the heterogeneity among studies of vitamin
B6 intake yielded a pooled RR of 0.80 (95% CI, 0.69-0.92). The risk of
colorectal cancer decreased by 49% for every 100-pmol/mL increase
(approximately 2 SDs) in blood PLP levels (RR, 0.51; 95% CI, 0.38-0.69).
Conclusion Vitamin B6 intake and blood PLP levels were inversely
associated with the risk of colorectal cancer in this meta-analysis.
October 2014 9

10. Vitamin D: intake of Vitamin D is associated with a 50% lower risk of developing
colorectal cancer.
Journal of Steroid Biochemistry & Molecular Biology
2005; 97: 179-194
Background
Inadequate photosynthesis or oral intake of Vitamin D are associated with
high incidence rates of colorectal cancer, but the dose–response relationship
has not been adequately studied.
Methods
Dose–response gradients from observational studies of Vitamin D intake and
serum 25-hydroxyvitamin D were plotted as trend lines. The point on each
linear trend line corresponding to an odds ratio of 0.50 provided the
prediagnostic Vitamin D intake or 25-hydroxyvitamin D concentration
associated with 50% lower risk compared to <100 IU/day Vitamin D or
<13 ng/ml serum 25-hydroxyvitamin D. Medians of these values were
determined.
Results
Overall, individuals with ≥1000 IU/day oral Vitamin D (p < 0.0001) or
≥33 ng/ml (82 nmol/l) serum 25-hydroxyvitamin D (p < 0.01) had 50% lower
incidence of colorectal cancer compared to reference values.
Conclusions
Intake of 1000 IU/day of Vitamin D, half the safe upper intake established by
the National Academy of Sciences, was associated with 50% lower risk.
Serum 25-hydroxyvitamin D of 33 ng/ml, which is known to be safe, also was
associated with 50% lower risk. Prompt public health action is needed to
increase intake of Vitamin D3 to 1000 IU/day, and to raise 25-hydroxyvitamin
D by encouraging a modest duration of sunlight exposure.
October 2014 10

11. Curcumin: possesses anti-cancer activity & potentiates the effect of chemotherapy in
colon and other cancers.
Abstract
The most practical approach to reduce the morbidity and mortality of
cancer is to delay the process of carcinogenesis through the use of
chemopreventive agents. This necessitates that safer compounds,
especially those derived from natural sources must be critically
examined for chemoprevention. A spice common to India and the
surrounding regions, is tur- meric, derived from the rhizome of
Curcuma longa. Pre-clinical studies in a variety of cancer cell lines
including breast, cervical, colon, gastric, hepatic, leukemia, oral
epithelial, ovarian, pancreatic, and prostate have consistently shown
that curcumin possesses anti-cancer activity in vitro and in pre-clinical
animal models. The robust activity of curcumin in colo- rectal cancer
has led to five phase I clinical trials being completed showing the
safety and tolerability of curcumin in colo- rectal cancer patients. To
date clinical trials have not identified a maximum tolerated dose of
curcumin in humans with clinical trials using doses up to 8000 mg per
day. The success of these trials has led to the development of phase II
trials that are currently enrolling patients. Overwhelming in vitro
evidence and completed clinical trials suggests that curcumin may
prove to be useful for the chemoprevention of colon cancer in
humans.
This review will focus on describing the pre- clinical and clinical
evidence of curcumin as a chemopreventive compound in colorectal
cancer. Published by Elsevier Ireland Ltd.
Cancer Letters 225 (2007) 170-181
October 2014 11

12. Dosages Matter
The Colon Vitamin Dose
% DV (Daily Value)
Typical Multi-vitamin Dose
%DV (Daily Value)
Micronutrients
Vitamin B2 3 mg, 176% 1.1 mg, 65%
Vitamin B6 3 mg, 150% 2 mg, 100%
Folate 500 mcg, 125% 400 mcg, 100%
Calcium 800 mcg, 80% 500 mg, 50%
Antioxidants
Beta Carotene 8,500 IU, 170% (Vitamin A) 1,014 IU, 20%
Vitamin D 1,000 IU, 250% 800 IU, 200%
Selenium 100 mcg, 143% 55 mcg, 79%
Curcumin 25 mg 0
October 2014 12

13. Delivering the right dosages to the right place at
the right time
White tablet releases calcium at a pH of 7.0 thus
delivering the calcium directly to the colon where
it can bind with fatty acids and bile acids in the colon*
Yellow tablet releases all of the other ingredients
into the small intestine where they are absorbed
into the bloodstream to effect their benefit
* Patent-pending formula. Developed by Dr. Frank Farrell, a gastroenterologist,
to promote colon health. He has been in clinical practice for nearly two decades
and is a Fellow of the American Gastroenterological Association.
October 2014 13

14. Summary
   
Contains micronutrients and
antioxidants that have been
shown in scientific studies to
promote colon health.*
Contains research-based
dosages to
deliver more effective
benefits.
Has a unique patent-pending
delivery
mechanism (SynerGI-dosing
®) to deliver the right
ingredients to the right
place at the right time.
Developed by a
gastroenterologist who is
well aware of the need
and the scientific
research to create the
solution.
For Endoscopy Centers & ASCs:
Ask for your free Patient Introductory Kit
• 50 cards redeemable for free 1-month supply
• Attractive display stand
• Educational brochure
Contact DrFarrell@TheColonVitamin.com
Here’s to your patients’ colon health!
* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
October 2014 14